The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

Non-animal testing methods could save drugmakers time and money, officials say ...

The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug developmen ...

Hood Patterson & Dewar’s Lee Howard and Jacob Rioux break down the pros, cons, and real-world challenges of grounding system ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...

In the past year, we have seen a growing interest and commitment to the environment at both the business and consumer levels. More businesses are focused on providing environmentally friendly products ...

A2LA-accredited Irvine lab explains why accredited vs. self-declared compliance determines COA acceptance by Amazon, ...

Along with the development of new instrumentation, the test procedure itself was also standardized. By “walking” the potential probe toward the current probe and graphing the measurements, the ...